Service agreement and financing facility supports strategic growth and commercialization initiatives LAS VEGAS, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTCQB: ODYY), a medical device company focused on developing and commercializing life-saving medical solutions, today announced it has entered into a multi-million-dollar, nine-year maintenance service contract for a commercial medical property. The long-term... Read More

Odyssey Medical Devices, Inc., a subsidiary of Odyssey Health Inc., to acquire exclusive global marketing and distribution rights for the BreastCheck® LAS VEGAS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTCQB: ODYY), a medical device company with a focus in life-saving medical solutions today announced that the company has signed a sub-licensing agreement for exclusive, worldwide rights to the BreastCheck ® ,... Read More

Company to Advance Development of its Patented Device LAS VEGAS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTCQB: ODYY) (the “Company” or “Odyssey”), a technology and asset acquisition company focused on developing unique, life-saving medical products is pleased to provide the following update on the development of its Save A Life (“SAL”) choking rescue device. Odyssey has created a prototype device and now... Read More

LAS VEGAS, NV / ACCESSWIRE / December 12, 2023 / Odyssey Health, Inc. (OTCOB:ODYY), a company focused on developing unique, life-enhancing medical products including a drug treatment intended to treat concussion, announces that it has received stockholder approval for the sale of its neurological drug platform technology. A Special Meeting of Odyssey stockholders was held on December 7, 2023, at the law offices of Brinen... Read More

LAS VEGAS, NV / ACCESSWIRE / November 16, 2023 / Odyssey Health, Inc. (OTCQB:ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, has selected Syneos Health ® , a leading fully integrated biopharmaceutical solutions organization to support its Investigational New Drug (IND) Application. Odyssey Health is developing a pharmaceutical treatment for mild... Read More

Odyssey Health, Inc. (OTC: ODYY ), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announces a Community-Based Partnership (CBP) with the David R. Metcalf Invisible Wounds Foundation, a non-profit organization that advances brain health care for active duty military and veterans by addressing traumatic brain injury (TBI) and suicide prevention among... Read More

Las Vegas Nevada, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, announces the launch of a concept phase to develop an intra-nasal field-deliverable nerve agent antidote. Chemical warfare using organophosphate nerve agents is a threat worldwide. The risk could not be higher for civilians and... Read More

Las Vegas, Nevada, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing life-enhancing medical products, today presents a Company update and recap of its product development programs. The Company has medical products in development which it intends to move forward in their respective clinical programs with the goal of FDA submission and... Read More

as Vegas, Nevada, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today presents a Company update and recap of its concussion drug development program. Concussions represent an ‘unmet’ medical need and affect tens of millions worldwide. Odyssey acquired the intellectual property and all rights... Read More

Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), announces that it has filed for United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device (“Nasal Device”). As announced, Odyssey’s recently completed Phase I study to treat concussion successfully used Odyssey’s Nasal Device and drug combination. Odyssey designed the... Read More

Odyssey Health, Inc . (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, announces the formation of Odyssey Neuropharma, Inc., a wholly owned subsidiary, focused on developing drugs to treat neurological disorders. The blood-brain barrier (BBB) represents a significant obstacle for drug delivery to the brain. Many drugs have failed in neuroscience... Read More

Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today presents a recap of their concussion drug development program. Concussions represent an ‘unmet’ medical need and affect millions worldwide. Repetitive concussions can increase the risk of developing Chronic Traumatic Encephalopathy (CTE) and other neuropsychiatric... Read More

Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., (the “Company” “Odyssey”) a company focused on developing a unique drug to treat concussion has decided to dissolve its sports advisory board. The sports advisory members have been outspoken advocates for concussion prevention and for the importance of finding responsible treatments. We created the advisory board to increase awareness of our mission... Read More

Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announces the completion of all cohorts for its Phase I Single Ascending Dosing (SAD) and Multiple Ascending Dosing (MAD) clinical trial. Odyssey’s trial involved administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. Throughout the... Read More

Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announced the successful completion of safety measures for the second cohort of their Phase I Multi-Day Ascending Dosing (MAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects to... Read More

Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announced the successful completion of safety measures for their Phase I Multi-Day Ascending Dosing (MAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. For MAD Cohort I, the drug was... Read More

Odyssey Health, Inc . (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-improving medical products, today announces the completion and safety findings from Cohort I of its Multi-Day Ascending Dosing (MAD) arm for its Phase I Clinical Trial. Odyssey’s trial is administering PRV-002, its novel drug to treat concussion, to healthy human subjects. MAD Cohort I subjects were dosed... Read More

Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products, is pleased to announce the launch of its new innovative corporate website: https://www.odysseyhealthinc.com/ . The new corporate website, like the Company’s previously announced name change, was designed to not only better reflect Odyssey Health’s mission and focus, but also improve... Read More

RedChip Companies will air a new interview with Odyssey Health, Inc. (OTC Pink:ODYY), f/k/a Odyssey Group International, Inc. , on The RedChip Money Report® on Bloomberg TV, this Saturday, July 16, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Brett Favre - Pro Football... Read More

Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announced the completion of all three cohorts in their Phase I Single Ascending Dosing (SAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. For SAD, the drug was safe and well... Read More

Odyssey Health, Inc . (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products, today announced positive safety findings from Cohort II of their Phase I clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. Data from Cohort II indicates that the drug was safe and... Read More

RedChip Companies will air a new C-Level interview with Odyssey Health, Inc . (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc. on The RedChip Money Report® on Bloomberg TV, this Saturday, June 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the US. RedChip’s CEO Dave Gentry interviews Odyssey’s CEO Michael Redmond in this exclusive interview, covering the questions... Read More

Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products, today announced positive safety findings from Cohort I of their Phase I clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. For Cohort I, the drug was safe and well tolerated. Concussions... Read More

Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products, today announced positive results from the first group of patients dosed with PRV-002, in their Phase I clinical trial. Odyssey’s trial is administering PRV-002, their novel drug to treat concussion, to healthy human subjects. Thus far the drug has shown to be safe and well... Read More

Odyssey Health, Inc. , formerly known as Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on developing a proprietary drug compound to treat concussion, is honored to welcome Vice Admiral (r) Timothy Szymanski to the Company’s prestigious Military Advisory Board. Odyssey’s drug candidate, PRV-002 is currently in a phase 1 clinical trial. “Too many service members and veterans... Read More

Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a medical technology company focused on developing unique, life-saving medical products, today announced the filing of a provisional patent on its novel nasal drug delivery device. The device and drug combination will be used in Odyssey’s sponsored current clinical trial for treating concussion. Odyssey’s breath powered nasal device is equipped with a... Read More

Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a medical company focused on developing unique, life-saving medical products, today announced successful completion of their clinical trial site initiation visit and the start of subject screening and enrollment. The drug candidate PRV-002 is being developed to treat concussion as a novel neurosteroid delivered nasally. Odyssey’s Phase 1 clinical... Read More

Odyssey Group International, Inc . (OTC: ODYY) (the "Company" or "Odyssey"), a health related company focused on developing unique, medical products including a treatment for concussion, today announced that its management team will give a corporate presentation at the HC Wainwright 23rd Annual Global Investment Conference. The conference is taking place virtually from September 13 - 15, 2021. Details for the presentation... Read More

Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a company focused on developing unique, life-saving medical products, today announced its approval to begin Phase 1 human clinical trials for drug candidate PRV-002 intended to treat concussions. The Company’s Clinical Trial Protocol was approved by the Alfred Ethics Committee and allows for the immediate start of the human trial. “We are elated to... Read More

Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique medical products, today announced the successful completion of their novel drug-device combination product to be administered in human clinical trials for treating concussion. After sustaining a concussion there is brain swelling, inflammation and oxidative stress. Odyssey has... Read More

Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a health related company focused on developing unique, medical products including a treatment for concussion, recently appeared on “Banfield” with Ashleigh Banfield. The appearance included members of its Sports Advisory Board to discuss the prevalence of concussions and the potential treatment that the Company is developing. The recorded interview... Read More

Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the successful completion of their Investigational New Drug (“IND”) enabling studies and submission of their Investigator’s Brochure (“IB”) for Ethics Committee review to begin Phase 1 clinical trials for the first in-human treatment... Read More

Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, medical products including a treatment for concussion, today announced members of its management team and Sports Advisory Board will appear on “Banfield” with Ashleigh Banfield. Odyssey Group International Appearance on “Banfield” Date: Tuesday, July 27, 2021 Time: 10:00 pm ET... Read More

Odyssey Group International, Inc. (OTCQB: ODYY) ("ODYY" or "the Company"), Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced it plans to hold the Annual Meeting of Stockholders of Odyssey Group International, Inc. in September, 2021. In order to be considered at the annual... Read More

Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products today announced the successful completion of their final system safety studies and cellular safety assays for entering clinical trials to treat concussion. The Company’s drug, PRV-002, will now receive a final safety review by the Clinical Trial... Read More

Odyssey Group International, Inc . (OTCQB: ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, announced today that its CEO, Michael Redmond, and Executive VP of Drug Development, Dr. Jake VanLandingham will present at the 2021 LD Micro Invitational XI Investor Conference. Presentation details: Date: Thursday, June 10, 2020 Time:... Read More

Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the completion of their novel nano-particle drug formulation. The drug formulation was designed to enhance brain distribution of its lead drug candidate, PRV-002, to treat concussion (mild traumatic brain injury). “The combined... Read More

Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the completion of the Food and Drug Administration (FDA) required toxicology studies designed to support clinical trials with PRV-002, its lead drug candidate to treat concussion (mild traumatic brain injury). Odyssey has also... Read More

Odyssey Group International, Inc. (OTCQB: ODYY) ("ODYY" or "the Company"), Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced it plans to hold the Annual Meeting of Stockholders of Odyssey Group International, Inc. on June 30, 2021. In order to be considered at the annual meeting,... Read More

Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the completion of the development of a novel nasal drug delivery device. The device was built in partnership with Design Catapult, Inc. The device will be used to deliver the Company’s drug candidate, PRV-002 for concussion... Read More

Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"),a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to welcome Ricky Richardson to the Company’s Board of Directors. Mr. Richardson has over 30 years of experience as a global operations and quality leader. He possesses operations and quality control experience that includes change... Read More

Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"),a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to welcome best selling author and award winning journalist Dr. Bob Arnot, M.D., to its Scientific Advisory Board (SAB). Dr. Arnot is the former Chief Medical Correspondent at Dateline NBC, The Today Show, NBC Nightly News, CBS News, CBS... Read More

Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the formation of a Scientific Advisory Board (SAB) with the appointment of leading experts in the fields of neurology, cardiology and preclinical drug development. The SAB will guide and advise the Company as it advances its... Read More

Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is honored to welcome retired United States National Soccer Team captain Abby Wambach to its Sports Advisory Board (SAB). The inaugural members of the SAB include notable professional athletes who have a passion to advance treatments for brain... Read More

CEO Michael Redmond to Highlight the Company's Strategy in Developing and Acquiring Life-Saving Medical Products Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced that its CEO, Michael Redmond, will present live to an online audience at the Q1 Virtual Investor Summit being held... Read More

Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce the formation of a Sports Advisory Board (SAB) to increase awareness regarding the unmet medical need for a treatment for brain injuries including concussion. The Company is in the pre-clinical phase of development of a drug... Read More

Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce that Dr. Jake VanLandingham, Odyssey's Vice President of Drug Development and the lead scientist developing PRV-002 will be joining Brett Favre to discuss the impact of concussions and the importance of this novel concussion... Read More

Anticipates initiation of Phase 1 clinical trials of PRV-002 during the Second Quarter of 2021 Odyssey Group International, Inc. (OTCQB:ODYY) ("Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce that it has closed the previously announced acquisition of drug candidate PRV-002, a novel neurosteroid being developed for the treatment of... Read More

Targets FDA Submission Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce that its collaboration with Tanaka Kapec Design Group (TKDG) has led to the completion of the design development phase for its Save A Life choking rescue device. Odyssey's patented Save A Life choking... Read More

Pre-clinical data for PRV-002, a nasally delivered drug in development for treating concussion, highlight rapid brain bioavailability Odyssey Group International, Inc. (OTCQB:ODYY) ("Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, and Prevacus Inc., are pleased to report the results of pre-clinical studies related to brain biodistribution of PRV-002... Read More

Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce multiple recent television segments focused on the development of a treatment for concussion by Prevacus', CEO Dr. Jake VanLandingham and Brett Favre. The appearances included: CheddarTV's "Closing Bell" on Friday, February 5... Read More

Provides Safer and Faster Access to the Brain Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce it is circulating a video to better define its drug candidate PRV-002, a therapeutic compound drug to treat concussion (mild traumatic brain injury (mTBI), from Prevacus Inc. For... Read More